Oncotarget

Research Papers:

HSPB1 deficiency sensitizes melanoma cells to hyperthermia induced cell death

He-Xiao Wang, Yang Yang, Hao Guo, Dian-Dong Hou, Song Zheng, Yu-Xiao Hong, Yun-Fei Cai, Wei Huo, Rui-Qun Qi, Li Zhang, Hong-Duo Chen and Xing-Hua Gao _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:67449-67462. https://doi.org/10.18632/oncotarget.11894

Metrics: PDF 1382 views  |   HTML 2305 views  |   ?  


Abstract

He-Xiao Wang1, Yang Yang1, Hao Guo1, Dian-Dong Hou1, Song Zheng1, Yu-Xiao Hong1, Yun-Fei Cai1, Wei Huo1, Rui-Qun Qi1, Li Zhang1, Hong-Duo Chen1, Xing-Hua Gao1

1Department of Dermatology, The First Hospital of China Medical University, Shenyang 110001, P.R. China

Correspondence to:

Xing-Hua Gao, email: gaobarry@hotmail.com

Keywords: hyperthermia, thermotolerance, HSPB1, combination strategy, melanoma

Received: December 14, 2015    Accepted: August 22, 2016    Published: September 08, 2016

ABSTRACT

Hyperthermia has shown clinical potency as a single agent or as adjuvant to other therapies in cancer treatment. However, thermotolerance induced by thermosensitive genes such as the heat shock proteins can limit the efficacy of hyperthermic treatment. In the present study, we identified HSPB1 (HSP27) is hyperthermically inducible or endogenously highly expressed in both murine and human melanoma cell lines. We used a siRNA strategy to reduce HSPB1 levels and showed increased intolerance to hyperthermia via reduced cell viability and/or proliferation of cells. In the investigation of underlying mechanisms, we found knock down of HSPB1 further increased the proportion of apoptotic cells in hyperthermic treated melanoma cells when compared with either single agent alone, and both agents leaded to cell cycle arrest at G0/G1 or G2/M phases. We concluded that hyperthermia combined with silencing of HSPB1 enhanced cell death and resulted in failure to thrive in melanoma cell lines, implying the potential clinical utility of hyperthermia in combination with HSPB1 inhibition in cancer treatment.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 11894